About: Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2007 (uk) article scientifique publié en 2007 (fr) artículu científicu espublizáu en setiembre de 2007 (ast) scientific article published on 01 September 2007 (en)
publication date	wds:Q81310348-AC24A36D-343E-45AE-B61A-37A1D144B390
publication date	2007-09-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q81310348-0B25DA51-4A53-42F2-9C1D-FB42C15A31AC wds:Q81310348-155FC00F-13B2-4532-8284-59FCAB2A6E63 wds:Q81310348-197A462C-F0C4-47A1-8044-895E0A484AF4 wds:Q81310348-226DE151-2232-4982-8C9F-3319D7ADC022 wds:Q81310348-419F2206-6FAC-407C-839E-50515F1B2A3F wds:Q81310348-4D6926AF-4CA8-40C1-84F7-DAD8029B5448 wds:Q81310348-4DF8E5F2-B093-4FC2-AB28-FC0E1091A264 wds:Q81310348-5A73AEDD-4BEA-4A5B-A280-9C29FF5F6D71 wds:Q81310348-6C712C28-F60D-4565-B951-0614E2EB893B wds:Q81310348-7BF4B9A7-4131-4D3C-92B6-5ACCCCE03251 wds:Q81310348-AB7A13EB-B8BD-4019-BBE9-30414A075782 wds:Q81310348-B1B30E25-87C1-46D0-A5CA-7E971E37EF60 wds:Q81310348-C07DE5D0-44A7-4AAE-B4DC-E68A038C5799 wds:Q81310348-D0293193-64DB-4F85-A785-D129C3B260BB wds:Q81310348-D2832E9C-2026-41EA-8D97-2497040FAB54 wds:Q81310348-D4B91717-61D1-4487-B9F2-9C4A583FB0F2 wds:Q81310348-EA8E5298-1AE4-43F6-AD94-988219288D03
author name string	Alice Chen James H Doroshow Min-Jung Lee William D Figg Anthony J Murgo Shivaani Kummar Eun Joo Chung Erin R Gardner Martin Gutierrez Erin Donovan Barbara Conley James Zwiebel Giovanni Melillo Kyunghwa Hwang Kim Maynard Mikhail Kalnitskiy Qin C Ryan
rdfs:label	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (en) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (nl)
skos:prefLabel	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (en) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (nl)
name	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (en) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (nl)
author	wds:Q81310348-C1738FC9-0FE2-4E2E-B277-4C13E4397FEE
author	Jane B Trepel
title	wds:Q81310348-C675473A-5A63-4D5A-A7FB-386AECF5C556
title	Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies (en)
page(s)	wds:Q81310348-3808FFEB-FC8E-4E45-8D9E-61272E2A986E
page(s)	5411-5417
instance of	wds:Q81310348-53794071-5139-4813-8385-14D4E752B7F0
instance of	scholarly article
main subject	wds:Q81310348-0620615B-4D11-4F4A-9CDA-84E2C735423D wds:Q81310348-B5C88BD6-C08F-4F3F-8715-537ACE35E6D2
main subject	entinostat phase I clinical trial
PubMed ID	wds:Q81310348-E4277EA2-BDFF-4123-B81C-0F11E58FA879
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17875771
PubMed ID	17875771
published in	wds:Q81310348-BF6BE0B3-9AD0-4CA8-9FA2-A07674E81AD2
published in	Clinical Cancer Research
issue	wds:Q81310348-ED4BBE53-CEBE-4997-8153-ED97E7AD1D0D
volume	wds:Q81310348-BDB4D2C0-8729-4A5D-BB74-AE4C83668D46
issue	18 Pt 1
volume	13
DOI	wds:Q81310348-D8D2310C-B876-48F8-B638-CC3B76A4946C
DOI	http://dx.doi.org/10.1158/1078-0432.CCR-07-0791
DOI	10.1158/1078-0432.CCR-07-0791
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81310348
is cites work of	Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat Clinical Toxicities of Histone Deacetylase Inhibitors Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Histone deacetylase inhibitors: current status and overview of recent clinical trials Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed Epigenetic modifiers: basic understanding and clinical development. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents The clinical development of histone deacetylase inhibitors as targeted anticancer drugs Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Histone deacetylase inhibitors in cancer therapy Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography Interpreting clinical assays for histone deacetylase inhibitors Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma HDAC modulation and cell death in the clinic Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo Targeting histone deacetylases for the treatment of disease Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software